Patent US4623619A successfully refreshed from Google Patents.
US4623619A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the determination of liability in human individuals to develop atherosclerosis
Assignee: Nordisk Insulinlaboratorium
•
Filing: 1983-02-18
•
Granted: 1986-11-18
•
Expires: 2003-02-18
Abstract
Abstract Liability in human individuals to develop non-insulin-dependent diabetes mellitus (NIDDM) and/or atherosclerosis is determined by restriction enzyme mapping of DNA from a human individual using a probe selected from the group consisting of (i) cDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20×10 6 base pairs from the insulin gene in either direction, and examining the distribution of DNA fragments for the appearance of insertion sequences of approximately 1600 to 2300 base pairs (U alleles) the occurrence of which indicates a liability for said individual to develop elevated blood glucose concentrations and/or atherosclerosis and in homozygous form a liability to develop NIDDM.
Inventors
- 👤 David Owerbach
- 👤 Jorn Nerup
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 01:52
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6813; C12Q1/6827; C12Q1/683; G; G01; G01T; G01T1/00; G01T1/29; G01T1/2914; G01T1/2921; G01T1/2942; C12Q2600/00; C12Q2600/156; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10T; Y10T436/00; Y10T436/14; Y10T436/142222; Y10T436/143333
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
120 words
A method for the determination of liability in human individuals to develop atherosclerosis which comprises the following steps: (a) providing a probe selected from the group consisting of (i) cDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20×10 6 base pairs of the insulin gene in either direction; (b) using said probe for restriction enzyme mapping of DNA from a human individual; (c) examining the distribution of DNA fragments for the appearance of insertion sequences of approximately 1600 to 2200 base pairs (U alleles); (d) the occurrence of said u allele indicating a liability for said individual to develop atherosclerosis.
Claim 2
Independent Claim
120 words
A method for the determination of liability in human individuals to develop atherosclerosis which comprises the following steps: (a) providing a probe selected from the group consisting of (i) cDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20×10 6 base pairs of the insulin gene in either direction; (b) using said probe for restriction enzyme mapping of DNA from a human individual; (c) examining the distribution of DNA fragments for the appearance of insertion sequences of approximately 1600 to 2200 base pairs (U alleles); (d) the occurrence of said u allele indicating a liability for said individual to develop atherosclerosis.
Claim 3
Dependent Claim
34 words
A method according to claim 1 in which the probe is human genomic DNA containing the insulin gene or DNA sequences up to 4000 base pairs upstream of the 5'-end of the insulin gene.
Claim 4
Dependent Claim
29 words
A method according to claim 1 in which the probe consists of DNA sequences derived from the Bgl I fragment of human genomic DNA which contains the insulin gene.
Claim 5
Dependent Claim
37 words
A method according to claim 3 in which the probe consists of DNA sequences from the Bgl I fragment in the region of from 0 to 4000 base pairs upstream of the 5'-end of the insulin gene.
Claim 6
Dependent Claim
66 words
A method according to claim 1 in which human DNA is treated with one or more restriction enzymes and the resulting fragments separated into fragments of different molecular mass by gel electrophoresis and transferred to a filter covalently binding the DNA, whereafter the filter is exposed to the radioactively labelled probe and binding of the probe to DNA fragments of specific sizes is identified by autoradiography.
Claim 7
Dependent Claim
45 words
A method according to claim 5 in which the restriction enzyme is Bgl I and the probe is a 32 P-labelled genomic DNA fragment containing insulin gene sequences, and that the fragment distribution is examined for the appearance of a fragment of approximately 4.8 kb.
References Cited (Backward Citations)
US4356270A
Cited
US4366246A
Cited
US4293652A
Cited
US4351901A
Cited
US4358535A
Cited
US4358535B1
Cited
US4419446A
Cited
US4411944A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-17 | 1990-05-19 | 1990-11-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-17 | 1994-05-19 | 1994-11-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-17 | 1998-05-19 | 1998-11-18 | $7700.00 | Window Closed / Lapsed |